Immix Biopharma Total Assets Over Time
| IMMX Stock | USD 1.79 0.11 6.55% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Immix Biopharma Performance and Immix Biopharma Correlation. Immix |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immix Biopharma. If investors know Immix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immix Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.84) | Return On Assets (0.57) | Return On Equity (1.04) |
The market value of Immix Biopharma is measured differently than its book value, which is the value of Immix that is recorded on the company's balance sheet. Investors also form their own opinion of Immix Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Immix Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immix Biopharma's market value can be influenced by many factors that don't directly affect Immix Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immix Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immix Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immix Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Total Assets Analysis
Compare Immix Biopharma and related stocks such as ZyVersa Therapeutics, Hepion Pharmaceuticals, and AVROBIO Total Assets Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZVSA | 685.6 K | 685.6 K | 685.6 K | 685.6 K | 685.6 K | 685.6 K | 685.6 K | 685.6 K | 685.6 K | 685.6 K | 685.6 K | 1.1 M | 118.5 M | 22.1 M | 39.2 M |
| HEPA | 86.7 K | 86.7 K | 86.7 K | 2 M | 2 M | 5.4 M | 13.1 M | 18.4 M | 8.2 M | 20.6 M | 48.6 M | 103.6 M | 60.2 M | 18.1 M | 27.5 M |
| CNSP | 162.2 K | 162.2 K | 162.2 K | 162.2 K | 162.2 K | 162.2 K | 162.2 K | 162.2 K | 683.3 K | 7.9 M | 15.9 M | 8.8 M | 13.1 M | 1.7 M | 1.6 M |
| SONN | 3.8 M | 5.5 M | 7.6 M | 20.1 M | 35.8 M | 42.2 M | 30.2 M | 39.8 K | 29.8 M | 8 M | 29 M | 5.8 M | 5.4 M | 29.8 M | 28.3 M |
| ENVB | 2.3 M | 22.4 K | 5.6 K | 4.5 K | 5.1 K | 13.8 M | 39.5 M | 52.2 M | 29.6 M | 25 M | 4.1 M | 26.7 M | 19.6 M | 4.3 M | 4.1 M |
| ELEV | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 80.9 M | 149.5 M | 94.2 M | 89.1 M | 91.4 M |
| OCEA | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 386 K | 79 K | 110.9 M | 127.5 M | 133.9 M |
Immix Biopharma and related stocks such as ZyVersa Therapeutics, Hepion Pharmaceuticals, and AVROBIO Total Assets description
Total assets refers to the total amount of Immix Biopharma assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Immix Biopharma books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.My Equities
My Current Equities and Potential Positions
| Immix Biopharma | IMMX |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 1.79
Additional Tools for Immix Stock Analysis
When running Immix Biopharma's price analysis, check to measure Immix Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immix Biopharma is operating at the current time. Most of Immix Biopharma's value examination focuses on studying past and present price action to predict the probability of Immix Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immix Biopharma's price. Additionally, you may evaluate how the addition of Immix Biopharma to your portfolios can decrease your overall portfolio volatility.